Stockscreener 앱 받기
0.79
0.01%
0.000100
Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스
APRE Forecast — Price Target — Prediction for 2027 - TradingView
Aprea Therapeutics, Inc. Actuals & Estimates (NASDAQ:APRE) - TradingView
Aprea Therapeutics Inc (APRE) Institutional Confidence - TradingKey
Aprea Therapeutics Inc (APRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Precision Medicine Strategies Expand Opportunities for Targeted Cancer Treatment, Says Dr Oren Gilad, Aprea Therapeutics - BioPharm International
Aprea Therapeutics Inc (APRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aprea Shareholders Approve Directors, Reverse Split Flexibility - The Globe and Mail
Aprea Therapeutics Inc (APRE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aprea Therapeutics Inc (APRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aprea Therapeutics Shareholders Approve Reverse Stock Split and Key Proposals at 2026 Annual Meeting - Minichart
Aprea Therapeutics Inc (APRE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aprea Therapeutics shareholders approve director elections and reverse stock split - Investing.com Nigeria
Aprea Therapeutics shareholders approve director elections and reverse stock split By Investing.com - Investing.com South Africa
Aprea Therapeutics Inc (APRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aprea Therapeutics Inc (APRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aprea Therapeutics Inc (APRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - Stocktwits
[Form 4] Aprea Therapeutics, Inc. Insider Trading Activity - Stock Titan
APRE: All agenda items, including director elections and reverse stock split, were approved - TradingView
Oppenheimer Initiates Aprea Therapeutics(APRE.US) With Buy Rating, Announces Target Price $5 - Moomoo
This Aprea Therapeutics analyst begins coverage on a bullish note; here are top 3 initiations for Thursday - MSN
Aprea Reports Early Tumor Responses in Phase 1 APR-1051 Study - MyChesCo
APRE Q1 2026 Earnings: Narrower Loss Surpasses Expectations Amid Ongoing Clinical DevelopmentManagement Guidance Update - newsline.com
APRE Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesSpecial Dividend Alert - newsline.com
APRE Q1 2026 Earnings: EPS Surpasses Estimates Amid Pre-Revenue StageEarnings Surprise Score - newsline.com
Aprea Expands Cancer Trial After Early Tumor Responses - MyChesCo
Aprea's WEE1 Drug Shows Early Promise in Hard-to-Treat Cancers - BriefGlance
H.C. Wainwright Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $1.2 - Moomoo
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors - The Manila Times
Cancer trial drug APR-1051 posts partial responses at ASCO 2026 - Stock Titan
Aprea Therapeutics (APRE) Edges Higher Amid Light Trading; Key Resistance at $0.99 in FocusOBV Divergence - The Legal Advocate
Aprea Therapeutics (APRE) Edges Higher Amid Low Volume TradingATR Stop - The Legal Advocate
Aprea Therapeutics Inc. (APRE) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Clinical ProgressAnalyst Drop Coverage - newsline.com
Aprea Therapeutics (APRE) upgraded to buy: Here's what you should know - MSN
Aprea Expands Cancer Trial After $30 Million Financing - MyChesCo
Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know - sharewise.com
Vestal Point reports 9.9% stake in Aprea Therapeutics (NASDAQ: APRE) - Stock Titan
Aprea Therapeuticsfiles for resale of up to 5.5 million shares by selling stockholdersSEC filing - marketscreener.com
[424B7] Aprea Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(7) - Stock Titan
Aprea Therapeutics 1Q Research and Development Expenses $1.6M >APRE - Moomoo
Wedbush Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target - TipRanks
Press Release: Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - Moomoo
Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating - Moomoo
Aprea Therapeutics, Inc. Q1 2026 10-Q Report – Financials, Risk Factors, and Forward-Looking Statements - Minichart
Aprea Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
1.36%
자본화:
|
볼륨(24시간):